Activity of single agent oxaliplatin in recurrent ovarian cancer, previously treated with cisplatin or carboplatin

ABSTRACT

This study included 28 females with recurrent ovarian cancer previously treated with combination chemotherapy including cisplatin or carboplatin. The platinum free interval was >6 - <12 months in 11 patients and >12 months in 17 patients. Oxaliplatin was prescribed in a dose of 130 mg/m2 administered over 2 hours every 21 days with an average of 5 cycles/patient. An overall response was achieved in ten patients with a median time to tumor progression and overall survival of 11 and 17 months, respectively. A favorable response was observed in the platinum sensitive group [platinum free interval of >12 months] as well as those cases with non-bulky recurrent disease. Oxaliplatin administration was associated with an accepted level of drug related toxicity